Role of N-Acetylcysteine in the Prevention of Radiocontrast-Induced Nephropathy

2002 ◽  
Vol 36 (9) ◽  
pp. 1466-1470 ◽  
Author(s):  
Donald F Brophy
Keyword(s):  
Renal Failure ◽  
Acute Renal Failure ◽  
Large Scale ◽  
English Language ◽  
Small Animal ◽  
Human Studies ◽  
Animal Trials ◽  
Study Selection ◽  
Risk Patients

OBJECTIVE: To examine the role of N-acetylcysteine (NAC) in the prevention of radiocontrast—induced nephropathy (RIN). DATA SOURCES: A literature search of MEDLINE (1966–December 2001) was performed using the following search terms: N-acetylcysteine, nephropathy, acute renal failure, and radiocontrast. STUDY SELECTION: Pertinent English-language animal and human studies were reviewed. DATA SYNTHESIS: Few small animal trials have demonstrated that NAC significantly prevents the development or reduces the severity of acute renal failure. Two human studies demonstrated NAC significantly reduces the occurrence of RIN. CONCLUSIONS: NAC may reduce the occurrence of RIN in high-risk patients. Further large-scale studies are needed to corroborate findings from earlier trials.

Acute Renal Failure in Hospitalized Patients: Part I

2002 ◽  
Vol 36 (7-8) ◽  
pp. 1261-1267 ◽  
Author(s):  
Maria C Pruchnicki ◽  
Joseph F Dasta
Keyword(s):  
Renal Failure ◽  
Acute Renal Failure ◽  
Data Extraction ◽  
Drug Effects ◽  
Hospitalized Patients ◽  
Medline Search ◽  
Study Selection ◽  
Risk Patients ◽  
Meta Analyses

BACKGROUND: Acute renal failure (ARF) is a common condition in hospitalized patients. Morbidity, mortality, and health resource use are considerable, but the true magnitude of the problem is not well described in the literature. OBJECTIVE: To provide a detailed discussion of the epidemiology, economic costs, and classification of ARF. DATA SOURCES: A MEDLINE search (1996–December 2001) was conducted using the search terms kidney and acute kidney failure: epidemiology, etiology, and drug therapy/drug effects. Bibliographies of selected articles were also examined to include all relevant investigations. Economic data were identified using the terms costs and cost analysis and cost of illness. STUDY SELECTION AND DATA EXTRACTION: Review articles, meta-analyses, and clinical trials describing epidemiology and classification of hospital-acquired ARF were identified. Results from prospective, controlled trials were given priority when available. CONCLUSIONS: ARF occurs in up to 25% of critically ill patients, resulting in significant morbidity and high mortality. Characterization of ARF is difficult due to multiple etiologic factors and variable definitions. Limited cost data describe the extensive economic burden associated with the disorder, although further pharmacoeconomic research is needed. Epidemiology and classification of ARF allow prospective management of at-risk patients.

scholarly journals Evaluating role of oxidative stress in determining the pathogenesis of falciparum malaria induced acute renal failure

2004 ◽  
Vol 19 (1) ◽  
pp. 93-96 ◽  
Author(s):  
Rachita Nanda ◽  
Pramila K. Mishra ◽  
U. K. Das ◽  
S. B. Rout ◽  
P. C. Mohapatra ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Renal Failure ◽  
Acute Renal Failure ◽  
Falciparum Malaria

scholarly journals Role of Nitric Oxide in Acute Renal Failure

Renal Failure ◽  
1997 ◽  
Vol 19 (2) ◽  
pp. 213-216 ◽  
Author(s):  
Luis Yu
Keyword(s):  
Nitric Oxide ◽  
Renal Failure ◽  
Acute Renal Failure

The Prevention of Acute Renal Failure in the Rat by Long-Term Saline Loading: A Possible Role of the Renin-Angiotensin Axis

1969 ◽  
Vol 131 (2) ◽  
pp. 610-614 ◽  
Author(s):  
F. D. McDonald ◽  
G. Thiel ◽  
D. R. Wilson ◽  
G. F. DiBona ◽  
D. E. Oken
Keyword(s):  
Renal Failure ◽  
Acute Renal Failure ◽  
Renin Angiotensin ◽  
Saline Loading

Role of Ambrisentan in the Management of Pulmonary Hypertension

2008 ◽  
Vol 42 (11) ◽  
pp. 1653-1659 ◽  
Author(s):  
Sandra L Hrometz ◽  
Kelly M Shields
Keyword(s):  
Pulmonary Hypertension ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
English Language ◽  
Data Extraction ◽  
Information Service ◽  
Study Selection ◽  
Pulmonary Arterial ◽  
Improve Exercise Capacity

Objective: To review the role of ambrisentan in the treatment of pulmonary arterial hypertension (PAH). Data Sources: Literature was accessed through MEDLINE (1950-June 2008), Iowa Drug Information Service (1966–March 2008), EMBASE (1966-June 2008), bibliographies of pertinent articles, and unpublished data provided by the manufacturer and the Food and Drug Administration (FDA). Search terms included ambrisentan, endothelin antagonist, pulmonary hypertension, and pulmonary arterial hypertension. Due to limited literature available, additional criteria to limit searches were not used. Study Selection and Data Extraction: Abstracts and original preclinical and clinical research reports available in the English language were Identified for review. All manufacturer-provided data were also evaluated. Literature related to ambrisentan, endothelin antagonists, pulmonary hypertension, and pulmonary arterial hypertension were included. Four clinical trials evaluated the efficacy of ambrisentan in adults with symptomatic PAH. Data Synthesis: Ambrisentan is the latest endothelin-receptor antagonist (ERA) to obtain FDA approval for the treatment of PAH. It joins the first FDA-approved ERA, bosentan. Like bosentan, ambrisentan is available orally (with once-daily dosing compared with bosentan's twice-daily dosing) and has been shown to improve exercise capacity and delay clinical worsening. As with bosentan, the most significant safety concerns with ambrisentan relate to potential liver injury and a contraindication in pregnancy. Although ambrisentan has higher affinity for the endothelin type A receptor than for the endothelin type B receptor, specific advantages of this selectivity, in terms of efficacy compared with bosentan, a nonselective agent, have not been demonstrated. Conclusions: Ambrisentan has been shown to be an effective ERA in patients with PAH. A significant advantage of ambrisentan is the lack of any clinically important drug interactions with warfarin and sildenafil, which are frequently used by patients being treated for PAH.

scholarly journals Meprin A metalloproteases enhance renal damage and bladder inflammation after LPS challenge

2009 ◽  
Vol 296 (1) ◽  
pp. F135-F144 ◽  
Author(s):  
Renee E. Yura ◽  
S. Gaylen Bradley ◽  
Ganesan Ramesh ◽  
W. Brian Reeves ◽  
Judith S. Bond
Keyword(s):  
Renal Failure ◽  
Acute Renal Failure ◽  
Urinary Tract ◽  
Nitrogen Levels ◽  
Lps Challenge ◽  
Lower Blood ◽  
Tnf Α ◽  
Meprin Metalloproteases ◽  
Membrane Bound

Meprin metalloproteases, composed of α and/or β subunits, consist of membrane-bound and secreted forms that are abundantly expressed in proximal tubules of the kidney as well as secreted into the urinary tract. Previous studies indicated that meprin metalloproteases play a role in pathological conditions such as ischemic acute renal failure and urinary tract infection. The aim of this work was to examine the role of meprins in endotoxemic acute renal failure using meprin α knockout (αKO), meprin β knockout (βKO), and wild-type (WT) mice. Differences among the responses of the genotypes were observed as early as 1 h after challenge with 2.5 mg/kg ip Escherichia coli LPS, establishing roles for meprins in the endotoxemic response. Meprin αKO mice displayed lower blood urea nitrogen levels and decreased nitric oxide levels, indicative of a decreased systemic response to LPS compared with WT and meprin βKO mice. Serum cytokine profiles showed lower levels of IL-1β and TNF–α in the meprin αKO mice within 3 h after LPS challenge and confirmed a role for meprins in the early phases of the host response. Meprin αKO mice were also hyporesponsive to LPS administered to the bladder, exhibiting significantly less bladder edema, leukocyte infiltration, and bladder permeability than WT mice. These data indicate that meprin A contributes to the renal and urogenital pathogenesis of endotoxicity.

The Pathogenesis of Experimental Acute Renal Failure: The Role of Membrane Dysfunction

1977 ◽  
pp. 73-115 ◽  
Author(s):  
Walter Flamenbaum ◽  
John H. Schwartz ◽  
Robert J. Hamburger ◽  
James S. Kaufman
Keyword(s):  
Renal Failure ◽  
Acute Renal Failure

Role of eicosanoids in sepsis-induced acute renal failure

1998 ◽  
pp. 551-556
Author(s):  
Bertrand Guidet ◽  
Laurent Baud
Keyword(s):  
Renal Failure ◽  
Acute Renal Failure
Sign in / Sign up

Export Citation Format

Share Document